TerminatedNot Applicable

Impact of C-arm CT in Decreased Renal Function Undergoing TACE for Tx of Hepato-Cellular Carcinoma

United States13 participantsStarted 2010-05

Plain-language summary

Impact on contrast dose or total volume of contrast required to effectively treat the targeted tumor.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients must be affected by HCC
✓. Patients must have diminished renal function (GFR\<60 ml/min/1.73m\^2)
✓. Patients must be 18 years old or older
✓. Patients must have received an abdominal CT, PET/CT scan or MRI, completed prior to the TACE procedure.
✓. Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

✕. Subjects under the age of 18
✕. Patients currently on dialysis
✕. Pregnant women

What they're measuring

Proportion of patients that develop renal failure (defined as a decline of renal function, as measured by glomerular filtration rate, of 25% or more from pre-procedural)

Timeframe: 3 weeks

Trial details

NCT IDNCT01326390

SponsorStanford University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2012-01

View on ClinicalTrials.gov More Kidney (Renal Cell) Cancer trials